| Line 509: | Line 509: | ||
*Citation: Pasquale Caponnetto, PhD, Jennifer DiPiazza, PhD, Jason Kim, MD, Marilena Maglia, Lyc Psych, Riccardo Polosa, MD, PhD, A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes, Nicotine & Tobacco Research, Volume 23, Issue 7, July 2021, Pages 1113–1122, doi:10.1093/ntr/ntab005 | *Citation: Pasquale Caponnetto, PhD, Jennifer DiPiazza, PhD, Jason Kim, MD, Marilena Maglia, Lyc Psych, Riccardo Polosa, MD, PhD, A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes, Nicotine & Tobacco Research, Volume 23, Issue 7, July 2021, Pages 1113–1122, doi:10.1093/ntr/ntab005 | ||
*Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength. | *Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength. | ||
===2021: [https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/ntab148/6322566 Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder]=== | |||
*Given the advent of novel, alternative tobacco products, Tobacco Use Disorder must be conceptualized within a contemporary framework that includes harm reduction and alternative outcomes. | |||
*[https://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntab148/39068104/ntab148.pdf PDF Version] | |||
*Citation: Amanda M Palmer, PhD, Benjamin A Toll, PhD, Matthew J Carpenter, PhD, Eric C Donny, PhD, Dorothy K Hatsukami, PhD, Alana M Rojewski, PhD, Tracy T Smith, PhD, Mehmet Sofuoglu, MD, PhD, Johannes Thrul, PhD, Neal L Benowitz, MD, On Behalf of the Society for Research on Nicotine & Tobacco Treatment Network, Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder, Nicotine & Tobacco Research, 2021;, ntab148, doi: 10.1093/ntr/ntab148 | |||
*Acknowledgement: This research was supported by by NIH Institutional Postdoctoral Training Grant NIHT32-HL144470, NIDA grant K01DA047433 (Smith), and NCI grant K07CA214839 (Rojewski), and the Hollings Cancer Center (P30 CA138313). | |||
edits